Clinical Trial

Radiotherapy - Adjuvant Versus Early Salvage

Study acronym: RAVES
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 18, 2022 (before its estimated December 2022 completion). Its status may not reflect the trial's current state.
Summary
Radical prostatectomy (RP) is the most common curative approach offered to men with newly diagnosed prostate cancer. Unfortunately, up to half of these patients will have factors placing them at high risk of their cancer recurring. Having radiotherapy after RP is known to improve cure rates, but what is not known is whether it should be given straight after the operation or only when there is a rising PSA after surgery indicating active cancer. Immediate RT may not benefit all men, and can cause serious side effects such as bladder and bowel problems and impotence. International lack of consensus on the optimal timing of RT has resulted in varied clinical practice. This phase 3 trial will compare the two approaches.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2009-03-11; most recent amendment 2022-11-16.
Status change: Recruiting → Active, Not Recruiting 2016-01-18
Trial Details
NCT Number NCT00860652
Lead Sponsor Trans Tasman Radiation Oncology Group
Collaborators: Urological Society of Australia and New Zealand (USANZ), Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Conditions Prostate Cancer
Enrollment 333 participants
Start Date 2009-03-03
Primary Completion 2022-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2022-11-18